{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T23:04:11Z","timestamp":1794351851742,"version":"4.9.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T00:00:00Z","timestamp":1791504000000},"content-version":"vor","delay-in-days":86,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Fondazione Umberto Veronesi","award":["Fellowship"],"award-info":[{"award-number":["Fellowship"]}],"id":[{"id":"https:\/\/ror.org\/041g7jm83","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Associazione Italiana per la Ricerca sul Cancro","award":["AIRC IG24324."],"award-info":[{"award-number":["AIRC IG24324."]}],"id":[{"id":"https:\/\/ror.org\/02g2x7380","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res"],"DOI":"10.1186\/s13058-026-02344-2","type":"journal-article","created":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T17:17:34Z","timestamp":1784135854000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Three ct-miRNA signature predicts disease outcome in early breast cancer women"],"prefix":"10.1186","volume":"28","author":[{"given":"Giulia","family":"Cosentino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mara","family":"Lecchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Giussani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Fogazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Galardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Tottone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Dell\u2019Orto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serenella M.","family":"Pupa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Verderio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elda","family":"Tagliabue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6058-1527","authenticated-orcid":false,"given":"Marilena V.","family":"Iorio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,15]]},"reference":[{"issue":"6","key":"2344_CR1","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1002\/cncr.27819","volume":"119","author":"AJ Tevaarwerk","year":"2013","unstructured":"Tevaarwerk AJ, Gray RJ, Schneider BP, Smith ML, Wagner LI, Fetting JH, et al. Survival in patients with metastatic recurrent breast cancer after adjuvant chemotherapy: little evidence of improvement over the past 30 years. Cancer. 2013;119(6):1140\u20138. https:\/\/doi.org\/10.1002\/cncr.27819.","journal-title":"Cancer 15 marzo"},{"issue":"24","key":"2344_CR2","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1093\/jnci\/81.24.1879","volume":"81","author":"MH Gail","year":"1989","unstructured":"Gail MH, Brinton LA, Byar DP, Corle DK, Green SB, Schairer C, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst. 1989;81(24):1879\u201386. https:\/\/doi.org\/10.1093\/jnci\/81.24.1879","journal-title":"J Natl Cancer Inst 20 dicembre"},{"issue":"3","key":"2344_CR3","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1002\/1097-0142(19940201)73:3<643::aid-cncr2820730323>3","volume":"73","author":"EB Claus","year":"1994","unstructured":"Claus EB, Risch N, Thompson WD. Autosomal dominant inheritance of early-onset breast cancer. Implications for risk prediction. Cancer. 1994;73(3):643\u201351. 10.1002\/1097-0142(19940201)73:3<643::aid-cncr2820730323>3.0.co;2-5.","journal-title":"Cancer 1 febbraio"},{"issue":"7","key":"2344_CR4","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1002\/sim.1668","volume":"23","author":"J Tyrer","year":"2004","unstructured":"Tyrer J, Duffy SW, Cuzick J. A breast cancer prediction model incorporating familial and personal risk factors. Stat Med. 2004;23(7):1111\u201330. https:\/\/doi.org\/10.1002\/sim.1668.","journal-title":"Stat Med 15 aprile"},{"issue":"2","key":"2344_CR5","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1200\/JCO.20.00853","volume":"39","author":"R Buus","year":"2021","unstructured":"Buus R, Sestak I, Kronenwett R, Ferree S, Schnabel CA, Baehner FL, et al. Molecular drivers of oncotype DX, prosigna, EndoPredict, and the breast cancer index: a transATAC Study. J Clin Oncol Off J Am Soc Clin Oncol. 2021;39(2):126\u201335. https:\/\/doi.org\/10.1200\/JCO.20.00853","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol 10 gennaio"},{"issue":"1","key":"2344_CR6","doi-asserted-by":"publisher","first-page":"18","DOI":"10.5644\/ama2006-124.239","volume":"48","author":"W Audeh","year":"2019","unstructured":"Audeh W, Blumencranz L, Kling H, Trivedi H, Srkalovic G. Prospective validation of a genomic assay in breast cancer: the 70-gene mammaprint assay and the MINDACT trial. Acta Med Acad. 2019;48(1):18\u201334. https:\/\/doi.org\/10.5644\/ama2006-124.239.","journal-title":"Acta Med Acad aprile"},{"issue":"1","key":"2344_CR7","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/s41523-024-00653-3","volume":"10","author":"F Panet","year":"2024","unstructured":"Panet F, Papakonstantinou A, Borrell M, Vivancos J, Vivancos A, Oliveira M. Use of ctDNA in early breast cancer: analytical validity and clinical potential. NPJ Breast Cancer. 2024;10(1):50. https:\/\/doi.org\/10.1038\/s41523-024-00653-3.","journal-title":"NPJ Breast Cancer 19 giugno"},{"issue":"1","key":"2344_CR8","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1038\/s41523-024-00706-7","volume":"10","author":"T Thomas-Bonafos","year":"2024","unstructured":"Thomas-Bonafos T, Pierga JY, Bidard FC, Cabel L, Kiavue N. Circulating tumor cells in breast cancer: clinical validity and utility. NPJ Breast Cancer. 2024;10(1):103. https:\/\/doi.org\/10.1038\/s41523-024-00706-7.","journal-title":"NPJ Breast Cancer 29 novembre"},{"issue":"1","key":"2344_CR9","doi-asserted-by":"publisher","first-page":"e29770","DOI":"10.1371\/journal.pone.0029770","volume":"7","author":"MG Schrauder","year":"2012","unstructured":"Schrauder MG, Strick R, Schulz-Wendtland R, Strissel PL, Kahmann L, Loehberg CR, et al. Circulating micro-RNAs as potential blood-based markers for early stage breast cancer detection. PloS One. 2012;7(1):e29770. https:\/\/doi.org\/10.1371\/journal.pone.0029770.","journal-title":"PLoS ONE"},{"issue":"10","key":"2344_CR10","doi-asserted-by":"publisher","first-page":"e13735","DOI":"10.1371\/journal.pone.0013735","volume":"5","author":"H Zhao","year":"2010","unstructured":"Zhao H, Shen J, Medico L, Wang D, Ambrosone CB, Liu S. A pilot study of circulating miRNAs as potential biomarkers of early stage breast cancer. PloS One. 2010;5(10):e13735. https:\/\/doi.org\/10.1371\/journal.pone.0013735.","journal-title":"PloS One"},{"issue":"16","key":"2344_CR11","doi-asserted-by":"publisher","first-page":"4028","DOI":"10.3390\/cancers13164028","volume":"13","author":"M Giussani","year":"2021","unstructured":"Giussani M, Ciniselli CM, De Cecco L, Lecchi M, Dugo M, Gargiuli C, et al. Circulating miRNAs as novel non-invasive biomarkers to aid the early diagnosis of suspicious breast lesions for which biopsy is recommended. Cancers. 2021;13(16):4028. https:\/\/doi.org\/10.3390\/cancers13164028.","journal-title":"Cancers 10 agosto"},{"issue":"68","key":"2344_CR12","doi-asserted-by":"publisher","first-page":"112170","DOI":"10.18632\/oncotarget.22750","volume":"8","author":"NH Farina","year":"2017","unstructured":"Farina NH, Ramsey JE, Cuke ME, Ahern TP, Shirley DJ, Stein JL, et al. Development of a predictive miRNA signature for breast cancer risk among high-risk women. Oncotarget. 2017;8(68):112170\u201383. https:\/\/doi.org\/10.18632\/oncotarget.22750.","journal-title":"Oncotarget 22 dicembre"},{"issue":"5","key":"2344_CR13","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41435-023-00220-z","volume":"24","author":"Y Lambrechts","year":"2023","unstructured":"Lambrechts Y, Garg AD, Floris G, Punie K, Neven P, Nevelsteen I, et al. Circulating biomarkers at diagnosis correlate with distant metastases of early luminal-like breast cancer. Genes Immun. 2023;24(5):270\u20139. https:\/\/doi.org\/10.1038\/s41435-023-00220-z.","journal-title":"Genes Immun ottobre"},{"issue":"5","key":"2344_CR14","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1158\/1078-0432","volume":"21","author":"K Kleivi Sahlberg","year":"2015","unstructured":"Kleivi Sahlberg K, Bottai G, Naume B, Burwinkel B, Calin GA, B\u00f8rresen-Dale AL, et al. A serum microRNA signature predicts tumor relapse and survival in triple-negative breast cancer patients. Clin Cancer Res Off J Am Assoc Cancer Res. 2015;21(5):1207\u201314. https:\/\/doi.org\/10.1158\/1078-0432.","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res 1 marzo"},{"issue":"1","key":"2344_CR15","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1111\/j.0006-341X.2001.00114.x","volume":"57","author":"G Heinze","year":"2001","unstructured":"Heinze G, Schemper M. A solution to the problem of monotone likelihood in Cox regression. Biometrics. 2001;57(1):114\u20139. https:\/\/doi.org\/10.1111\/j.0006-341X.2001.00114.x.","journal-title":"Biometrics marzo"},{"issue":"12","key":"2344_CR16","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1016\/0895-4356(95)00048-8","volume":"48","author":"P Peduzzi","year":"1995","unstructured":"Peduzzi P, Concato J, Feinstein AR, Holford TR. Importance of events per independent variable in proportional hazards regression analysis II. Accuracy and precision of regression estimates. J Clin Epidemiol. 1995;48(12):1503\u201310. https:\/\/doi.org\/10.1016\/0895-4356(95)00048-8","journal-title":"J Clin Epidemiol dicembre"},{"issue":"12","key":"2344_CR17","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1016\/0895-4356(95)00510-2","volume":"48","author":"J Concato","year":"1995","unstructured":"Concato J, Peduzzi P, Holford TR, Feinstein AR. Importance of events per independent variable in proportional hazards analysis I. Background, goals, and general strategy. J Clin Epidemiol. 1995;48(12):1495\u2013501. https:\/\/doi.org\/10.1016\/0895-4356(95)00510-2.","journal-title":"J Clin Epidemiol dicembre"},{"issue":"5","key":"2344_CR18","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1002\/sim.4780080504","volume":"8","author":"S Durrleman","year":"1989","unstructured":"Durrleman S, Simon R. Flexible regression models with cubic splines. Stat Med. 1989;8(5):551\u201361. https:\/\/doi.org\/10.1002\/sim.4780080504.","journal-title":"Stat Med maggio"},{"issue":"1","key":"2344_CR19","doi-asserted-by":"publisher","first-page":"315","DOI":"10.3892\/ol.2016.5452","volume":"13","author":"S Pizzamiglio","year":"2017","unstructured":"Pizzamiglio S, Zanutto S, Ciniselli CM, Belfiore A, Bottelli S, Gariboldi M, et al. A methodological procedure for evaluating the impact of hemolysis on circulating microRNAs. Oncol Lett. 2017;13(1):315\u201320. https:\/\/doi.org\/10.3892\/ol.2016.5452.","journal-title":"Oncol Lett gennaio"},{"issue":"1","key":"2344_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/bjc.2016.164","volume":"115","author":"P Verderio","year":"2016","unstructured":"Verderio P, Bottelli S, Pizzamiglio S, Ciniselli CM. Developing miRNA signatures: a multivariate prospective. Br J Cancer. 2016;115(1):1\u20134. https:\/\/doi.org\/10.1038\/bjc.2016.164.","journal-title":"Br J Cancer 28 giugno"},{"key":"2344_CR21","doi-asserted-by":"publisher","first-page":"1398922","DOI":"10.3389\/fonc.2024.1398922","volume":"14","author":"J Zheng","year":"2024","unstructured":"Zheng J, Zeng B, Huang B, Wu M, Xiao L, Li J. A nomogram with Nottingham prognostic index for predicting locoregional recurrence in breast cancer patients. Front Oncol. 2024;14:1398922. https:\/\/doi.org\/10.3389\/fonc.2024.1398922.","journal-title":"Front Oncol"},{"issue":"34","key":"2344_CR22","doi-asserted-by":"publisher","first-page":"55231","DOI":"10.18632\/oncotarget.10485","volume":"7","author":"D Huo","year":"2016","unstructured":"Huo D, Clayton WM, Yoshimatsu TF, Chen J, Olopade OI. Identification of a circulating microRNA signature to distinguish recurrence in breast cancer patients. Oncotarget. 2016;7(34):55231\u201348. https:\/\/doi.org\/10.18632\/oncotarget.10485.","journal-title":"Oncotarget 23 agosto"},{"issue":"3","key":"2344_CR23","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1158\/0008-5472.CAN-19-1425","volume":"80","author":"C Chiodoni","year":"2020","unstructured":"Chiodoni C, Cancila V, Renzi TA, Perrone M, Tomirotti AM, Sangaletti S, et al. Transcriptional profiles and stromal changes reveal bone marrow adaptation to early breast cancer in association with deregulated circulating microRNAs. Cancer Res. 2020;80(3):484\u201398. https:\/\/doi.org\/10.1158\/0008-5472.CAN-19-1425.","journal-title":"Cancer Res 1 febbraio"},{"issue":"6","key":"2344_CR24","doi-asserted-by":"publisher","first-page":"876","DOI":"10.3390\/cancers11060876","volume":"11","author":"M Incoronato","year":"2019","unstructured":"Incoronato M, Grimaldi AM, Mirabelli P, Cavaliere C, Parente CA, Franzese M, et al. Circulating miRNAs in untreated breast cancer: an exploratory multimodality morpho-functional study. Cancers. 2019;11(6):876. https:\/\/doi.org\/10.3390\/cancers11060876.","journal-title":"Cancers 22 giugno"},{"issue":"16","key":"2344_CR25","doi-asserted-by":"publisher","first-page":"7065","DOI":"10.1158\/0008-5472.CAN-05-1783","volume":"65","author":"MV Iorio","year":"2005","unstructured":"Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, Sabbioni S, et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Res. 2005;65(16):7065\u201370. https:\/\/doi.org\/10.1158\/0008-5472.CAN-05-1783.","journal-title":"Cancer Res"},{"key":"2344_CR26","doi-asserted-by":"publisher","first-page":"2639","DOI":"10.2147\/OTT.S102713","volume":"9","author":"L Hong","year":"2016","unstructured":"Hong L, Pan F, Jiang H, Zhang L, Liu Y, Cai C, et al. miR-125b inhibited epithelial-mesenchymal transition of triple-negative breast cancer by targeting MAP2K7. OncoTargets Ther. 2016;9:2639\u201348. https:\/\/doi.org\/10.2147\/OTT.S102713.","journal-title":"OncoTargets Ther"},{"issue":"1","key":"2344_CR27","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/s13287-025-04227-3","volume":"16","author":"M Jiang","year":"2025","unstructured":"Jiang M, Liu J, Hu S, Yan X, Cao Y, Wu Z. Exosomal miR-125b-5p derived from mesenchymal stromal\/stem cell enhances anti-PD-1 therapy in mouse colon cancer model. Stem Cell Res Ther. 2025;16(1):112. https:\/\/doi.org\/10.1186\/s13287-025-04227-3.","journal-title":"Stem Cell Res Ther 5 marzo"},{"issue":"11","key":"2344_CR28","doi-asserted-by":"publisher","first-page":"e005241","DOI":"10.1136\/jitc-2022-005241","volume":"10","author":"M Jiang","year":"2022","unstructured":"Jiang M, Yang Y, Niu L, Li P, Chen Y, Liao P, et al. MiR-125b-5p modulates the function of regulatory T cells in tumor microenvironment by targeting TNFR2. J Immunother Cancer. 2022;10(11):e005241. https:\/\/doi.org\/10.1136\/jitc-2022-005241.","journal-title":"J Immunother Cancer"},{"issue":"4","key":"2344_CR29","doi-asserted-by":"publisher","first-page":"919","DOI":"10.7150\/jca.33696","volume":"11","author":"C Zhang","year":"2020","unstructured":"Zhang C, Wan X, Tang S, Li K, Wang Y, Liu Y, et al. miR-125b-5p\/STAT3 Pathway regulated by mTORC1 plays a critical role in promoting cell proliferation and tumor growth. J Cancer. 2020;11(4):919\u201331. https:\/\/doi.org\/10.7150\/jca.33696.","journal-title":"J Cancer"},{"issue":"2","key":"2344_CR30","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3390\/ncrna10020016","volume":"10","author":"R Piergentili","year":"2024","unstructured":"Piergentili R, Marinelli E, Cucinella G, Lopez A, Napoletano G, Gullo G, et al. miR-125 in breast cancer etiopathogenesis: an emerging role as a biomarker in differential diagnosis, regenerative medicine, and the challenges of personalized medicine. Non-Coding RNA. 2024;10(2):16. https:\/\/doi.org\/10.3390\/ncrna10020016.","journal-title":"Non-Coding"},{"issue":"28","key":"2344_CR31","doi-asserted-by":"publisher","first-page":"21496","DOI":"10.1074\/jbc.M109.083337","volume":"285","author":"M Zhou","year":"2010","unstructured":"Zhou M, Liu Z, Zhao Y, Ding Y, Liu H, Xi Y, et al. MicroRNA-125b confers the resistance of breast cancer cells to paclitaxel through suppression of pro-apoptotic Bcl-2 antagonist killer 1 (Bak1) expression. J Biol Chem. 2010;285(28):21496\u2013507. https:\/\/doi.org\/10.1074\/jbc.M109.083337.","journal-title":"J Biol Chem"},{"issue":"1","key":"2344_CR32","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s12860-022-00432-7","volume":"23","author":"Y Peng","year":"2022","unstructured":"Peng Y, Huang X, Wang H. lncRNA ACTA2-AS1 predicts malignancy and poor prognosis of triple-negative breast cancer and regulates tumor progression via modulating miR-532-5p. BMC Mol Cell Biol. 2022;23(1):34. https:\/\/doi.org\/10.1186\/s12860-022-00432-7.","journal-title":"BMC Mol Cell Biol"},{"key":"2344_CR33","doi-asserted-by":"publisher","first-page":"144104","DOI":"10.1016\/j.gene.2019.144104","volume":"722","author":"X Zou","year":"2020","unstructured":"Zou X, Li M, Huang Z, Zhou X, Liu Q, Xia T, et al. Circulating miR-532-502 cluster derived from chromosome X as biomarkers for diagnosis of breast cancer. Gene. 2020;722:144104. https:\/\/doi.org\/10.1016\/j.gene.2019.144104.","journal-title":"Gene"},{"issue":"1","key":"2344_CR34","doi-asserted-by":"publisher","first-page":"400","DOI":"10.3892\/etm.2019.8186","volume":"19","author":"L Huang","year":"2020","unstructured":"Huang L, Tang X, Shi X, Su L. miR-532-5p promotes breast cancer proliferation and migration by targeting RERG. Exp Ther Med. 2020;19(1):400\u20138. https:\/\/doi.org\/10.3892\/etm.2019.8186.","journal-title":"Exp Ther Med"},{"issue":"11","key":"2344_CR35","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1002\/kjm2.12261","volume":"36","author":"Y Ma","year":"2020","unstructured":"Ma Y, Zhao HX, Shi YJ, Cheng MG. MicroRNA-532-5p is a prognostic marker and inhibits the aggressive phenotypes of osteosarcoma through targeting CXCL2. Kaohsiung J Med Sci. 2020;36(11):885\u201394. https:\/\/doi.org\/10.1002\/kjm2.12261.","journal-title":"Kaohsiung J Med Sci"},{"issue":"9","key":"2344_CR36","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1016\/j.febslet.2011.04.018","volume":"585","author":"XX Liu","year":"2011","unstructured":"Liu XX, Li XJ, Zhang B, Liang YJ, Zhou CX, Cao DX, et al. MicroRNA-26b is underexpressed in human breast cancer and induces cell apoptosis by targeting SLC7A11. FEBS Lett. 2011;585(9):1363\u20137. https:\/\/doi.org\/10.1016\/j.febslet.2011.04.018.","journal-title":"FEBS Lett"},{"issue":"1","key":"2344_CR37","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/1475-2867-13-7","volume":"13","author":"J Li","year":"2013","unstructured":"Li J, Kong X, Zhang J, Luo Q, Li X, Fang L. MiRNA-26b inhibits proliferation by targeting PTGS2 in breast cancer. Cancer Cell Int. 2013;13(1):7. https:\/\/doi.org\/10.1186\/1475-2867-13-7.","journal-title":"Cancer Cell Int 1 febbraio"},{"issue":"2","key":"2344_CR38","doi-asserted-by":"publisher","first-page":"R40","DOI":"10.1186\/bcr3644","volume":"16","author":"S Tan","year":"2014","unstructured":"Tan S, Ding K, Li R, Zhang W, Li G, Kong X, et al. Identification of miR-26 as a key mediator of estrogen stimulated cell proliferation by targeting CHD1, GREB1 and KPNA2. Breast Cancer Res. 2014;16(2):R40. https:\/\/doi.org\/10.1186\/bcr3644.","journal-title":"Breast Cancer Res"},{"key":"2344_CR39","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.omtn.2020.08.015","volume":"22","author":"L Meng","year":"2020","unstructured":"Meng L, Liu S, Liu F, Sang M, Ju Y, Fan X, et al. ZEB1-mediated transcriptional upregulation of circWWC3 promotes breast cancer progression through activating ras signaling pathway. Mol Ther Nucleic Acids 19 agosto. 2020;22:124\u201337. https:\/\/doi.org\/10.1016\/j.omtn.2020.08.015","journal-title":"Mol Ther Nucleic Acids 19 agosto"}],"container-title":["Breast Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13058-026-02344-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-026-02344-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-026-02344-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T02:50:59Z","timestamp":1791514259000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13058-026-02344-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,15]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2344"],"URL":"https:\/\/doi.org\/10.1186\/s13058-026-02344-2","relation":{},"ISSN":["1465-542X"],"issn-type":[{"value":"1465-542X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,15]]},"assertion":[{"value":"29 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"For the Retrospective Cohort, Institutional approval from our independent ethics committee was obtained for this study (approval numbers INT111-13, INT144-14). For BABE samples, Institutional approval from our independent ethics committee was obtained for this study (approval numbers INT66-15).","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"172"}}